US Stock Futures Signal Higher Start On Wall Street

Pre-open movers US stock futures traded higher in early pre-market trade. Futures for the Dow Jones Industrial Average jumped 94 points to 17,743.00, while the Standard & Poor's 500 index futures rose 11.80 points to 2,047.10. Futures for the Nasdaq 100 index climbed 23.50 points to 4,224.25. A Peek Into Global Markets European markets were higher today, with the Spanish Ibex Index rising 1.30%, STOXX Europe 600 Index gaining 0.98% and German DAX 30 index gaining 1.57%. French CAC 40 Index jumped 1.54% and London's FTSE 100 Index rose 0.37%. In Asian markets, Hong Kong's Hang Seng Index climbed 0.45%, China's Shanghai Composite Index slipped 1.71% and India's Sensex jumped 0.46% Broker Recommendation Analysts at JMP Securities downgraded Morgan Stanley MS from Market Outperform to Market Perform and removed the price target of $38.00. Morgan Stanley's shares closed at $36.88 on Friday. Breaking news
  • QIAGEN NV QGEN announced today the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess an important genomic mutation in patients with non-small cell lung cancer (NSCLC), the most common form of this cancer. To read the full news, click here.
  • Foundation Medicine, Inc. FMI and Roche RHHBY announced today that they will enter into a broad strategic collaboration to further advance Foundation Medicine's market-leading position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. To read the full news, click here.
  • Auspex Pharmaceuticals, Inc. ASPX today announced favorable topline safety results from its thorough QT (TQT) clinical trial evaluating the effects of SD-809 on cardiac repolarization, based on placebo-corrected, time-matched changes from baseline in the corrected QT (QTc) interval. To read the full news, click here.
  • Shire PLC SHPG has agreed to acquire NPS Pharmaceuticals, Inc. NPSP for $5.2 billion or $46 a share. To read the full news, click here.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsJMP SecuritiesUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!